Compare ADNT & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADNT | PVLA |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | Ireland | United States |
| Employees | N/A | 29 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2016 | N/A |
| Metric | ADNT | PVLA |
|---|---|---|
| Price | $20.40 | $138.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 15 |
| Target Price | $25.41 | ★ $171.87 |
| AVG Volume (30 Days) | ★ 1.1M | 285.1K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $17,439,000,000.00 | N/A |
| Revenue This Year | $2.71 | N/A |
| Revenue Next Year | $2.36 | $104,350.18 |
| P/E Ratio | $335.17 | ★ N/A |
| Revenue Growth | ★ 7.56 | N/A |
| 52 Week Low | $17.68 | $34.57 |
| 52 Week High | $27.32 | $161.38 |
| Indicator | ADNT | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 50.98 |
| Support Level | $19.96 | $106.07 |
| Resistance Level | $21.76 | $156.88 |
| Average True Range (ATR) | 0.75 | 11.22 |
| MACD | 0.20 | -1.80 |
| Stochastic Oscillator | 87.38 | 52.02 |
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.